Infectious Diseases News and Research

RSS

GenVec to receive $2.3M from NIAID for HIV vaccine candidate production

GenVec, Inc. announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its third option period (year four) under a previously announced, five-year contract with GenVec valued at up to $52 million for the production of HIV vaccines.

26 Sep 2009

Virginia Tech student granted fellowship for research study on LaCrosse Virus disease

Camille Harris of Ridgeland, Mississippi, a graduate student in biological sciences at Virginia Tech, has been awarded a National Institutes of Health (NIH) Graduate Research Fellowship for her study of forest disturbance and its ecological impacts on LaCrosse Virus, a mosquito-borne disease that can cause seizures, coma, paralysis, and permanent brain damage in severe cases.

26 Sep 2009

Associated Press/Washington Post examine contributions of military research to reducing global disease burden

In light of the U.S. Army's announcement yesterday that an experimental HIV vaccine trial it is sponsoring in Thailand showed modest potential for preventing infection, the Associated Press/Washington Post examines how military research is contributing to the fight against major diseases around the world.

25 Sep 2009

Recent releases in Global Health

A study appearing in the Journal of Infectious Diseases explores how well access to safe drinking water reduces rates of diarrhea experienced by 6-month-old infants born to HIV-infected mothers following weaning.

25 Sep 2009

Non-AIDS-defining malignancies more prevalent among HIV-infected patients than non-HIV patients

Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.

25 Sep 2009

Caliper Life Sciences unveils XenoLight Rediject reagents series at WMIC

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced a series of XenoLight Rediject reagents at the World Molecular Imaging Congress (WMIC) in Montreal, Canada. Rediject D-Luciferin Ultra is the latest in an expanding range of XenoLight reagents for Caliper's IVIS optical imaging systems.

25 Sep 2009

iCo Therapeutics, CPDD sign collaboration development agreement

iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that the company has signed a collaboration development agreement with The Consortium for Parasitic Drug Development (CPDD) for the research and development of iCo's oral drug delivery technology for the treatment of neglected diseases such as leishmaniasis and trypanosomiasis. Initial funding of USD $182,930 will be provided for formulation optimization for tropical conditions.

25 Sep 2009

Phase III clinical trial of investigational HIV vaccine regimen complete

Global Solutions for Infectious Diseases (“GSID”) announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.

25 Sep 2009

Partial success reported in the Phase 3 trial of HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases.

25 Sep 2009

Investigational vaccine shows modest potential for protecting against HIV infection

For the first time, scientists say an investigational vaccine has modest potential for protecting people against HIV infection, the Associated Press reports. "The vaccine — a combination of two previously unsuccessful vaccines — cut the risk of becoming infected with HIV by ... 31 percent in the world's largest [HIV] vaccine trial of more than 16,000 volunteers in Thailand, researchers announced Thursday in Bangkok," the news service writes (Marchione/Casey, 9/24).

25 Sep 2009

Experimental HIV vaccine shows promise

An experimental HIV vaccine raises hope of reducing the risk of infection. Wall Street Journal/Associated Press reports: "For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible."

25 Sep 2009

NTMs: Rising cause of severe lung diseases

Nontuberculous mycobacteria (NTM) are environmental organisms found in both water and soil that can cause severe pulmonary (lung) disease in humans. Pulmonary NTM is on the rise in the United States, according to a large study of people hospitalized with the condition.

25 Sep 2009

H1N1 influenza pandemic could present a host of medical ethics issues: JCB

The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion.

25 Sep 2009

Researchers study functional similarity between zebrafish and humans to fight infections

Since the human response to infection is highly complex, research to understand how people fight infection is facilitated by studying how similar processes occur in simpler organisms. Zebrafish are becoming an important model for human disease, since they are easily handled, maintained and manipulated and many fundamental processes between zebrafish and humans are conserved.

24 Sep 2009

Mandell, Douglas, and Bennett's publication on infectious diseases released

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th Edition. Marking 30 years since its initial publication, it remains the most respected reference source of its kind, and maintains its relevance in the face of the emergence of newly recognized infectious diseases, including new strains of the swine (H1N1) and avian influenza viruses.

24 Sep 2009

Researchers to discuss ways to develop mathematical control theory methods for ABMs at NIMBioS workshop

Agent-based models (ABMs) are powerful computer-simulation modeling techniques that used increasingly to understand a broad range of biological phenomena, such as tumor growth, the immune system, and the spread of infectious diseases through a population.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

NIH awards three UNC Scientists for high risk and innovative research

Three scientists from the University of North Carolina at Chapel Hill School of Medicine and the UNC Lineberger Comprehensive Cancer Center have received prestigious awards from the National Institutes of Health (NIH) aimed at encouraging "high risk" and innovative research.

24 Sep 2009

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of infectious diseases and a late-stage oncology company, announced today that it has hired a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment.

24 Sep 2009

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."

24 Sep 2009

Infectious Diseases News and Research

GenVec to receive $2.3M from NIAID for HIV vaccine candidate production

Virginia Tech student granted fellowship for research study on LaCrosse Virus disease

Associated Press/Washington Post examine contributions of military research to reducing global disease burden

Recent releases in Global Health

Non-AIDS-defining malignancies more prevalent among HIV-infected patients than non-HIV patients

Caliper Life Sciences unveils XenoLight Rediject reagents series at WMIC

iCo Therapeutics, CPDD sign collaboration development agreement

Phase III clinical trial of investigational HIV vaccine regimen complete

Partial success reported in the Phase 3 trial of HIV/AIDS vaccine

Investigational vaccine shows modest potential for protecting against HIV infection

Experimental HIV vaccine shows promise

NTMs: Rising cause of severe lung diseases

H1N1 influenza pandemic could present a host of medical ethics issues: JCB

Researchers study functional similarity between zebrafish and humans to fight infections

Mandell, Douglas, and Bennett's publication on infectious diseases released

Researchers to discuss ways to develop mathematical control theory methods for ABMs at NIMBioS workshop

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

NIH awards three UNC Scientists for high risk and innovative research

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News